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ABSTRACT Respiratory syncytial virus (RSV) is the leading cause of severe respira-
tory illness in infants. At this young age, infants typically depend on maternally
transferred antibodies (matAbs) and their innate immune system for protection
against infections. RSV-specific matAbs are thought to protect from severe illness,
yet severe RSV disease occurs mainly below 6 months of age, when neutralizing
matAb levels are present. To investigate this discrepancy, we asked if disease sever-
ity is related to antibody properties other than neutralization. Some antibody effec-
tor functions are mediated via their Fc binding region. However, it has been shown
that this binding may lead to antibody-dependent enhancement (ADE) of infection
or reduction of neutralization, both possibly leading to more disease. In this study,
we first showed that high levels of ADE of RSV infection occur in monocytic THP-1
cells in the presence of RSV antibodies and that neutralization by these antibodies
was reduced in Vero cells when they were transduced with Fc gamma receptors. We
then demonstrated that antibodies from cotton rats with formalin-inactivated (FI)-
RSV-induced pulmonary pathology were capable of causing ADE. Human matAbs
also caused ADE and were less neutralizing in vitro in cells that carry Fc receptors.
However, these effects were unrelated to disease severity because they were seen
both in uninfected controls and in infants hospitalized with different levels of RSV
disease severity. We conclude that ADE and reduction of neutralization are unlikely
to be involved in RSV disease in infants with neutralizing matAbs.
IMPORTANCE It is unclear why severity of RSV disease peaks at the age when in-
fants have neutralizing levels of maternal antibodies. Additionally, the exact rea-
son for FI-RSV-induced enhanced disease, as seen in the 1960s vaccine trials, is
still unclear. We hypothesized that antibodies present under either of these con-
ditions could contribute to disease severity. Antibodies can have effects that
may lead to more disease instead of protection. We investigated two of those ef-
fects: antibody-dependent enhancement of infection (ADE) and neutralization
reduction. We show that ADE occurs in vitro with antibodies from FI-RSV-
immunized RSV-infected cotton rats. Moreover, passively acquired maternal anti-
bodies from infants had the capacity to induce ADE and reduction of neutraliza-
tion. However, no clear association with disease severity was seen, ruling out
that these properties explain disease in the presence of maternal antibodies. Our
data contribute to a better understanding of the impact of antibodies on RSV
disease in infants.
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Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tractdisease in young children (1). Hospitalization for severe RSV-mediated disease is
most frequent between 6 weeks and 6 months of life (2, 3). It seems widely accepted
that RSV-neutralizing, transplacentally transferred maternal antibodies (matAbs) can
lower the risk for RSV infections (1, 4, 5); however, many studies fail to reproduce these
results (6–8). There is no consensus on what level of antibodies is sufficient for
protection, but an average concentration of maternal antibodies seems insufficient.
Maternal antibody levels are high during the first 6 months after birth. Strikingly,
severe RSV disease most frequently occurs in this period of life (2, 3), indicating RSV can
infect infants even though matAbs are present. For these children who become
infected with RSV, the role of matAbs in RSV disease is unclear. Associations between
the severity of symptoms and classical serological parameters such as RSV neutraliza-
tion titer or RSV-specific antibody levels have not been observed so far (4, 6). However,
antibodies have additional effector functions, generally mediated via their Fc binding
region, that contribute to immune defense. In this study, we investigate whether
consequences of antibody-Fc receptor interactions could be related to the severity of
symptoms during RSV infection.
Antibody-dependent enhancement (ADE) of RSV infection has been demonstrated
in vitro (9) in monocytic cell lines. ADE means that RSV-specific antibodies in human
serum, as well as monoclonal antibodies, increase the number of RSV-infected cells
when those cells carry Fc gamma receptors (FCGR) (10, 11). FCGR-carrying leukocytes,
which are present in the lungs or recruited during infection, might be more readily
infected and activated by RSV-antibody complexes than RSV alone. In addition to
causing ADE, Fc receptors lower the RSV neutralization capacity of most monoclonal
antibodies (12), allowing RSV to infect even in the presence of otherwise neutralizing
antibody titers. Whether FCGR binding influences RSV (immuno-)pathology and sever-
ity of RSV disease has not been studied so far, but the ongoing pursuit of RSV vaccines
demands more knowledge about the role of antibodies in RSV disease. Therefore, we
investigated whether reduced neutralization and enhanced RSV infection of FCGR-
bearing cells by maternal antibodies that should provide passively acquired immunity
relates to clinical disease severity in infants. Moreover, antibodies generated as part of
active immunity induced by formalin-inactivated (FI)-RSV vaccination have been shown
to contribute to enhanced pathology (13). Therefore, we also investigated whether
reduced neutralization and enhanced RSV infection of FCGR-bearing cells relates to
pathology in the FI-RSV cotton rat model.
We assessed two FCGR-mediated effects of RSV-specific antibodies: antibody-
dependent enhancement of infection in monocytic THP-1 cells and reduction of
neutralization capacity in cells transduced with Fc gamma receptors. Both were inves-
tigated for passively transferred matAbs by titration series of plasma from human cord
blood and for actively acquired antibodies from immunized cotton rats, a small-animal
model that is highly susceptible to RSV and shows vaccine-enhanced pulmonary
pathology (14, 15). To assess possible associations with disease severity, plasma sam-
ples from infants with acute primary RSV infection were tested, as were sera from
cotton rats showing FI-RSV-induced enhancement of pathology.
RESULTS
ADE of RSV infection and PRNT50. Infants that encounter RSV in the first months
of life have maternal antibodies. Despite the presence of maternal antibodies, a subset
of infants that encounter RSV become severely ill. The antibodies of severely diseased
infants are not neutralizing enough to prevent infection, but they can induce multiple
other effector functions through FCGR interactions. In this paper, we investigate the
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impact of these Fc receptor-mediated functions of maternal antibodies on the severity
of disease symptoms during RSV infection. We assessed two antibody-Fc receptor-
mediated effects in vitro: antibody-dependent enhancement (ADE) and reduction of
RSV neutralization (change in 50% plaque reduction neutralization titers, or ΔPRNT50).
ADE of RSV infection in the presence of human serum or RSV-specific monoclonal
antibodies has been demonstrated previously in monocytic cell lines, which carry Fc
receptors (10, 11). ADE of RSV infection can be induced by subneutralizing concentra-
tions of antibodies. At low concentrations, antibodies are not able to neutralize
infection but bind RSV and mediate binding to Fc receptors. This attachment and
subsequent internalization facilitates higher infection rates than those in the absence
of antibodies and is schematically illustrated for monocytic THP-1 cells in Fig. 1A.
The second effect we investigated is the ability of the FCGR to reduce the neutral-
ization capacity (PRNT50) of antibodies. Antibodies have higher neutralization potential
on cells lacking FCGR than the same cell type expressing FCGR, as is shown for
wild-type Vero cells compared to Vero cells expressing FCGR (12). We called this change
in neutralization mediated by FCGR ΔPRNT50 throughout the manuscript (Fig. 1B).
ΔPRNT50 represents the factor of reduction of neutralization and is calculated by
dividing the PRNT50 in Vero cells by the PRNT50 in Vero cells expressing FCGR2a
(Vero2a).
ADE in primary cells and monocytic cell line THP-1. ADE of RSV infection in the
presence of human serum has been demonstrated previously (10). To investigate the
effect of serum antibodies only and exclude the effect of other serum components, we
used purified human immunoglobulin (IVIg). Serial dilutions of IVIg neutralized RSV (0%
normalized infection) at high antibody concentrations and then facilitated up to 300%
FIG 1 Antibody-dependent enhancement (ADE) and reduction of neutralization (ΔPRNT50) of RSV
infection. Schematic figure depicting the calculation of ADE in THP-1 cells (A) and ΔPRNT50 between WT
and FCGR-transduced Vero cells (B).
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infection compared to the condition without antibodies (100% normalized infection) in
monocytic, FCGR-carrying THP-1 cells (Fig. 2A, arrow points to maximum infection
enhancement). Commercially available pooled human AB serum and a pool of cord
blood plasma, both containing nonimmunoglobulin components, showed similar titra-
tion curves. Maximum ADE was similar for the three antibody solutions (Fig. 2B). To
confirm that ADE is mediated by antibody-FCGR interactions in THP-1 cells, FLIPr-like
protein was supplemented, which blocks FCGR-mediated Fc binding. FLIPr-like protein
reduced ADE from 340% to 125% infection for IVIg (Fig. 2C). To assess whether ADE can
occur in primary cells, we performed an ADE assay using human PBMCs. Also in primary
immune cells, RSV infection was enhanced up to 230% (Fig. 2D).
PRNT50 on FCGR2a-expressing Vero cells as measure for FCGR-mediated
reduction of neutralization. Eliciting RSV-neutralizing antibodies is the primary goal
of RSV vaccination efforts. Intriguingly, the presence of FCGRs in target cells mostly
reduces the RSV neutralization capacity of monoclonal antibodies (12). Preventing Fc
receptor interactions restored RSV neutralization by IVIg in THP-1 cells (Fig. 2C). We
previously demonstrated that the impact of FCGRs on RSV neutralization can be
measured in Vero cells that stably express FCGR2a (Vero2a) (12). In this study, titration
series of IVIg, pooled human AB serum, and pooled cord blood plasma revealed a
4-fold-reduced neutralization on Vero2a compared to parental Vero cells (Fig. 3A to D).
Although reduction in neutralization can be measured, FCGR-expressing Vero cells
show no ADE, which is in line with observations for dengue virus (DenV) (16).
Interindividual variation in ADE and PRNT50. To further analyze ADE or
ΔPRNT50 and any link to disease symptoms, we first assessed whether it would be
feasible to distinguish between individuals with different capacities of ADE and
ΔPRNT50. We tested the two Fc-mediated effects in cord blood from 15 individual
donors. Most samples showed about 400% ADE compared to infection in the absence
of antibodies (Fig. 4A). The ΔPRNT50 showed a larger individual variation with up to
FIG 2 Antibody-dependent enhancement in monocytic cell line THP-1 and primary cells. (A) RSV neutralization assay using FCGR-carrying
THP-1 cells in the presence of serially diluted IVIg, human serum, or cord blood. (B) ADE is reported for the dilution at which infection is
maximal (depicted by the arrow in panel A). Fc-binding sites of FCGRs were blocked by adding 3 g/ml staphylococcal FLIPr-like protein
to THP-1 cells during RSV neutralization assay. (D) RSV neutralization assay using cells that were isolated from human blood (human
PBMCs). One representative graph of three PBMC donors is depicted. For other graphs, the means and standard deviations (SD) from 3
individual experiments are shown.
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10-fold reduction of RSV neutralization in Vero2a cells (Fig. 4B). Interestingly, the
ΔPRNT50 was unrelated to ADE (Fig. 4C), indicating that they are independent effects.
ADE and PRNT50 do not correlate with RSV neutralization or anti-RSV IgG
levels. To investigate a possible contribution of classical antibody characteristics to
ADE or ΔPRNT50, both phenotypes were compared to two classical serological param-
eters: RSV neutralization in Vero cells (Fig. 5A and B) and amount of RSV-specific IgG
(Fig. 5C and D). Slightly more reduction of neutralization was detected when RSV
neutralization titers were highest (Fig. 5B), but this was not significant. No associations
between any of the other parameters were detected.
ADE in primary cells from cotton rat lungs. ADE of RSV infection has not been
demonstrated in vivo, but the inoculation of mice with RSV in complex with antibodies
has been shown to reshape the immune response compared to RSV alone (17). Natural
RSV infections target pulmonary tissue; therefore, we tested cells derived from lungs of
naive cotton rats. To determine the type of cells in these lung cell isolates, we stained
the cells for the epithelial marker pancytokeratin (18) and T cell marker CD3 (19). Only
3% of cells were of epithelial origin, whereas 35% of cells were CD3 positive (data not
shown). This indicated that a large proportion of isolated cells were immune cells. Pools
of plasma from RSV-challenged animals enhanced RSV infection in these cells by 330%
(Fig. 6A). No ADE was induced when serum from naive cotton rats was used, indicating
the requirement of RSV-specific antibodies for ADE.
Characterization of FI-RSV-induced antibodies in immunized cotton rats. As
cotton rat antibodies could enhance RSV infection in primary cells, we wanted to
understand their effect on RSV disease. It has been shown that antibodies generated as
part of active immunity induced in infants by FI-RSV vaccination contribute to en-
hanced pathology (13). The cotton rat provides a model for FI-RSV-induced RSV
pulmonary pathology (15). Therefore, we investigated whether reduced neutralization
and enhanced RSV infection of FCGR-bearing cells relates to pathology in the FI-RSV
cotton rat model.
FIG 3 Reduction of neutralization of RSV in FCGR2a-transduced Vero cells. (A to C) RSV neutralization assays
using parental and FCGR2a-transduced Vero cells (Vero2a) in the presence of serially diluted IVIg, human
serum, or cord blood. (D) The ΔPRNT50 is a measure for the reduction of neutralization titer in Vero2a cells
calculated by dividing PRNT50[Vero] by PRNT50[Vero2a] (depicted by the arrows in panels A to C). Means
and SD from 3 individual experiments are shown.
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Animals were immunized with FI-RSV for nonprotective antibodies or recombinant
live-attenuated RSV (rRSV) for protective immunity. First, RSV-specific antibodies in
cotton rats were characterized. RSV neutralization in Vero cells demonstrated low,
dose-dependent titers of neutralizing antibodies in all FI-RSV-immunized animals,
whereas neutralization capacity of plasma from animals immunized with rRSV was high
(Fig. 6B). Correspondingly, RSV-specific antibody levels were low after FI-RSV and high
after rRSV immunization (Fig. 6C).
The ability of cotton rat antibodies to cause ADE in the human THP-1 cell model was
assessed next. Plasma of all immunized animals caused ADE in THP-1 cells (Fig. 6D).
Infection was increased by 580% for plasma from rRSV-immunized animals and 380%
after FI-RSV immunization. The dilution at which maximum ADE was measured was low
for low-dose FI-RSV-, intermediate for high-dose FI-RSV-, and highest for rRSV-
immunized animals. This corresponds to RSV neutralization titers and RSV-specific
antibody levels. ΔPRNT50 could not be determined for the cotton rat sera due to a lack
of neutralizing capacity, making it impossible to calculate a PRNT50.
Serum of cotton rats with lung pathology causes ADE in the absence of
neutralization. To assess the relationship between ADE of RSV infection and severity
of pulmonary pathology in cotton rats, pathology after RSV challenge of FI-RSV- or
rRSV-immunized cotton rats was studied. Affirming previous studies, immunization
with rRSV protected the animals and resulted in little pathology after challenge
FIG 4 ADE and ΔPRNT50 by maternal antibodies. ADE (A) and ΔPRNT50 (B) were determined for 15
individual cord blood samples. (C) Statistical dependence between ADE and ΔPRNT50 was tested by
Spearman’s correlation.
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(Fig. 7A). Both FI-RSV-immunized groups showed elevated lung pathology compared to
the group treated with rRSV or the mock vaccine. Moreover, the level of subepithelial,
periarterial, and bronchiolar infiltrate was higher in FI-RSV-immunized cotton rats than
in the control groups in our study. This is in accordance with the increased lymphocyte
infiltration in FI-RSV-vaccinated children and animals in previous studies (20, 21).
The ADE and RSV neutralization titers of cotton rat sera next were compared to the
sum of pathology scores (cumulative pathology score). Sera from mock-immunized
animals were excluded. The capacity to induce ADE was present in all sera that
contained RSV-specific antibodies independent of the pathology score. More ADE
appears to be linked to lower levels of pathology, although the difference in ADE over
the range of pathology was small (Fig. 7B). A lower pathology score might concur with
efficient RSV neutralization and high anti-RSV antibody levels (Fig. 6B and C). The latter
was confirmed, as pathological consequences of RSV challenge were high when RSV
neutralization titers were low (Fig. 7C). Thus, antibodies from cotton rats with FI-RSV-
induced pulmonary pathology were weak neutralizers and capable of causing ADE
in vitro.
ADE and PRNT50 do not correlate with RSV disease outcome in hospitalized
infants. As ADE measured in vitro might relate to severe disease in vivo in the absence
of neutralization, a possible association between severity of symptoms in infants and
ADE or ΔPRNT50 was investigated. Plasma from hospitalized patients with an acute
primary RSV infection was analyzed. As this is not a prospective study, the ideal control
group of RSV-infected children with mild symptoms was not available, because blood
of these children is not routinely sampled. A common practice in RSV research is to use
age-matched uninfected infants as controls. One assumes that this group is not
protected and if healthy infants become RSV infected, a vast majority (98 to 99%) would
develop only mild symptoms (22). Analysis of the plasma samples showed that RSV
neutralization and epitope specificity did not correlate with severity of symptoms (6).
The lack of this correlation indicates there is no bias for antibody concentration or
neutralization in each disease group. Therefore, this is an ideal sample set to assess ADE
and ΔPRNT50 on FCGR-expressing cells.
FIG 5 ADE and ΔPRNT50 are independent of classical serological parameters. ADE and ΔPRNT50 of 15 individual
cord blood samples were compared to the RSV neutralization titer in Vero cells (A and B) or the relative amount
of RSV-specific IgG (C and D). Associations were tested with Spearman’s correlation.
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First, maximum ADE of RSV infection by plasma from uninfected, moderate, and
severe disease groups was examined on THP-1 cells. ADE ranged from 400 to 1,000%
of infection, showing a greater variation than that in cord blood samples. However,
disease severity and average ADE were not related (Fig. 8A). The plasma titer at which
ADE was maximal next was calculated for all samples. The infants with moderate RSV
disease had a significantly higher ADE titer than the uninfected controls, but no
correlation with severe disease could be found (Fig. 8B). On Vero2a cells, the ΔPRNT50
ranged from 1- to 4-fold-reduced neutralization (Fig. 8C), but the average ΔPRNT50 was
similar in all groups. We also checked correlation between ADE, ΔPRNT50, and age, but
no relation was found (data not shown).
DISCUSSION
Serum concentration and neutralization capacity are of primary concern when
assessing the antiviral activity of antibodies. However, antibodies have many other
functions, mediated by the Fc region, that play a role in the immune response. On
FCGR-bearing cells, the antibody-FCGR interaction may lead to antibody-dependent
enhancement (ADE) of infection or to reduction of neutralization (ΔPRNT50). We
performed this study because we were intrigued by the fact that most severe RSV cases
occur in RSV patients under the age of 6 months, when relatively high levels of
RSV-neutralizing matAbs can be found. Moreover, infants that experienced vaccine-
enhanced disease after the 1960s FI-RSV trials had an RSV-specific antibody response,
albeit nonprotective. Therefore, both of these maternal and FI-RSV-induced antibodies
could have a detrimental role in RSV-mediated disease when not neutralizing enough
to protect infants from infection.
Generally, Fc-mediated effector functions of RSV-specific antibodies are not consid-
ered when studying acute RSV disease, even though some studies demonstrated ADE
FIG 6 ADE by RSV-specific cotton rat antibodies. (A) RSV neutralization assay using cells that were isolated from cotton rat lungs.
Plasma pools were from naive () or wild-type RSV-infected () cotton rats. (B to D) Four animals per group were immunized with
live RSV (rRSV) or medium (mock) or with a low- or high-dose FI-RSV or formalin-treated medium (FI-mock) and subsequently
challenged with RSV. (B and C) RSV neutralization titer (B) and RSV-specific IgG (C) of cotton rat plasma on day 4 after challenge. OD
450 nm, optical density at 450 nm. (D) RSV neutralization assay using THP-1 cells to determine the maximum ADE of cotton rat plasma.
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of RSV infection in vitro, including an increase of ADE after RSV infection (9–11, 23).
RSV-specific matAbs may cause ADE and reshape the immune response against RSV
(17, 23, 24). Interestingly, matAbs against dengue virus (DenV) have been suggested to
worsen DenV disease in infants (25, 26).
We investigated whether FCGR interactions of RSV-specific serum antibodies relate
to the severity of RSV disease symptoms in different settings. ADE of RSV infection and
ΔPRNT50 were studied in FCGR-bearing cells using plasma from naive children with
severe RSV disease, cord blood plasma, and plasma from FI-RSV-immunized cotton rats
showing pathology. There are clear differences between severe RSV disease in naive
infants, which fully depend on maternal antibodies for RSV-specific immunity, and
FI-RSV vaccine-induced pathology, which is mediated by pathogenic vaccine-induced
antibodies in the presence of an unbalanced cellular response (27). For example, FI-RSV
vaccine-enhanced pulmonary pathology is associated with inadequate cellular immune
responses (28–30). Another well-established difference is the low RSV neutralization
capacity of serum antibodies induced by FI-RSV vaccination (13, 31, 32). The use of sera
from two different types of RSV disease allowed us to assess the ADE and
neutralization-reducing characteristics for both passively acquired matAbs and actively
acquired antibodies in a vaccination setting.
ADE was seen for plasma of both healthy and severely ill infants in different degrees,
but we did not find a correlation between ADE and RSV disease. There are several
considerations to be made. First, it is well described that ADE is related to more disease
severity in DenV (33–35). However, there are fundamental differences between DenV
and RSV infection. Only a single serotype exists for RSV, whereas heterotypic, nonneu-
tralizing antibodies exacerbate DenV disease. In addition, the primary target cells for
RSV are lung epithelial cells, in contrast to immune cells for DenV. Interestingly, there
is a growing body of evidence that RSV also infects immune cells. Recently, infection of
several subsets of immune cells has been found in infants with severe RSV disease (36,
FIG 7 Lung pathology in cotton rats that show ADE in vitro in the absence of neutralization. Four animals per group were immunized with
live RSV (rRSV) or medium only (mock) or with low- or high-dose FI-RSV or formalin-treated medium (FI-mock) and subsequently
challenged with RSV. Intra-epith., intraepithelial; peribronch. infiltr., peribronchial infiltrate. (A) Histopathologic lung pathology scores. (B
and C) Cumulative pathology scores, calculated by the sum of individual pathology scores, were compared to ADE and PRNT50 by
Spearman’s correlation.
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37). Infection of these FCGR-carrying immune cells may well be aided by ADE, which
could affect the immune response and subsequent pathology, as in DENV infections.
Second, our study demonstrates that ADE of RSV in vitro occurs only at nonneu-
tralizing concentrations of antibodies. Even minute amounts of antibodies that fail to
neutralize can mediate ADE. Such conditions may have existed in some of the infants
in our study. Bronchial antibody concentrations can be about 100 times lower than
those in circulation, where we measured them (38–40), and RSV-specific matAbs can
decline rapidly, with a half-life of approximately 1 month (3). Such an age-dependent
decline of matAbs has been described in DenV infections and has been suggested to
increase the risk for severe disease (41, 42). Interestingly, in contrast to most RSV-
specific monoclonal antibodies, neutralization by palivizumab improves in cells ex-
pressing FCGR (12). This unique feature of the therapeutic monoclonal antibody might
explain its clinical efficacy.
Third, our findings on maternal antibodies from children with various levels of RSV
disease were different from findings on antibodies from cotton rats that show vaccine-
enhanced pulmonary pathology mediated by FI-RSV-induced immune responses. In
children, neither ADE nor reduced neutralization correlated with disease severity, but
in FI-RSV-immunized cotton rats high ADE capacity in vitro coincides with pathology in
FIG 8 ADE and ΔPRNT50 by plasma from patients with different severities of RSV-mediated disease
symptoms. RSV neutralization assays using plasma samples from patients with moderate or severe
RSV-mediated disease and healthy control patients (uninfected). Maximum ADE (A) and plasma titer at
which ADE was maximal (B) were compared to disease severity. (C) ΔPRNT50 was compared to disease
severity. Statistical analyses employed one-way analysis of variance for comparison between the three
disease groups (**, P  0.01).
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the absence, but not in the presence, of neutralization, as seen for rRSV-immunized
animals. This suggests that ADE cannot induce severe pathology in the presence of
neutralization but should be considered under nonneutralizing conditions.
Although various reports do emphasize the importance of antibodies in vaccine-
enhanced RSV disease (13, 31, 32, 43), it is generally accepted that FI-RSV vaccine-
enhanced pathology results from an unbalanced immune response and a combination
of aberrant humoral and cellular responses. In animal models, CD4 T cells seem to be
especially important mediators of pathology (28, 30). Interestingly, such a requirement
for the FCGR-carrying cellular arm of the immune system might explain why RSV-
specific antibodies have a low probability of influencing disease through ADE in the
absence of a cellular response, as is the case with maternally derived antibodies. It
would also be in accordance with data from a previous study in which it was shown
that passive transfer of serum from FI-RSV-immunized cotton rats to naive animals was
not sufficient to induce vaccine-enhanced disease (44). This does not exclude that such
antibodies in their original setting (i.e., acquired through immunization) and in com-
bination with immune cells could play a role in disease, but only when they are
nonneutralizing, as is the case in FI-RSV-immunized animals.
Our data show that severe pulmonary pathology in the cotton rat FI-RSV vaccination
model occurs in the presence of antibodies that are nonneutralizing and cause ADE
in vitro. This relation may also exist in humans: since the initial demonstration that the
formalin-inactivated vaccine enhanced disease severity in children, ADE has been
considered an explanation (45). FI-RSV-immunized infants developed nonneutralizing
antibody titers, a prerequisite for ADE, possibly because formalin treatment of RSV
modified the viral surface epitopes (11, 46). Correspondingly, vaccine-enhanced pa-
thology was partially attributed to increased levels of nonneutralizing antibodies and
immune complex deposition in previous reports (13, 31, 32, 43). This could lead to
augmented RSV infection of immune cells that carry FCGR and/or reshaping of the
immune response by FCGR signaling.
Recently, it has been shown that binding of immune complexes to FCGR is not
enough to induce ADE for Ebola virus (47). Downstream signaling pathways were
required to observe enhancement of infection. This may explain why we were unable
to detect ADE on the FCGR-transduced Vero cells. Most likely, the FCGRs expressed on
Vero cells are nonfunctional in signaling; they only mediate the binding of immune
complexes and cannot internalize the RSV-antibody immune complexes.
We show that there is ADE capacity in vitro when RSV-mediated pathology and
RSV-specific antibodies are present. However, additional research is needed to eluci-
date the involvement of ADE in infection of immune cells in vivo during natural RSV
infection or after vaccination. We did not see a correlation between ADE in vitro and
disease severity for the infants in our cohort with the assays described in this paper.
However, multiple additional antibody functions that may have immunomodulatory
effects have not been tested yet (reviewed in reference 48). In addition, using THP-1
cells as a model system only demonstrates the effect on monocytes, whereas other
immune cells express different combinations of FCGRs and could react differently. It
could well be that ADE is part of a set of conditions, including the status of the infant’s
immune system or airway size, that determine the outcome of RSV infection.
In summary, antibodies can favor ADE and have reduced neutralization capacity in
Fc receptor-carrying cells. Antibodies from FI-RSV-immunized cotton rats showed no
neutralization and were able to induce ADE in vitro. In infants, ADE and reduced
neutralization by matAbs in vitro did not relate to severity of RSV disease symptoms,
although all tested human plasma had the capacity to cause ADE. There may be
different effects from passively transferred matAbs compared to antibodies induced by
direct vaccination, particularly when they are nonneutralizing, as we show for those
induced by formalin-inactivated vaccines. This could lead to different outcomes of ADE.
This report shows that ADE should not be ignored as a possible player in RSV
infection. Most importantly, the induction of nonneutralizing antibodies or subneutral-
izing antibody titers should be avoided. It remains a challenge to find out whether
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immune cells are infected through ADE of RSV infection in vivo. It should also be noted
that RSV infection of immune cells may have multiple effects, ranging from (hyper)ac-
tivation to shutting down cellular effector functions. Any of these effects could lead to
the known contribution of immune cells to immunopathology in severe RSV-mediated
disease. Determining whether ADE of RSV infection is possible in these cells in vivo and
how these cells react may provide clues to why severe RSV disease occurs in certain
cases and how we can prevent the burden of disease in these young infants.
MATERIALS AND METHODS
Study design. Plasma samples from healthy controls and hospitalized infants with RSV infections
used in this study have been described before (6). Hospitalized children below 1 year of age with
PCR-confirmed RSV infections were included during 2011 to 2013. In the previous study, only samples
from children below 3 months of age were included (6). In this study, we included all 51 children, of
which 20% were 3 months of age. Blood samples were taken within 24 h after admission. Patients with
congenital heart or lung disease, immunodeficiency, or glucocorticoid use and infants born at a
gestational age below 35 weeks were excluded. For analysis, patients were classified with severe
symptoms when they required mechanical ventilation and admission to the intensive care unit. Infants
with moderate disease were only monitored or received oxygen therapy. Infants below 1 year of age
requiring surgery for an inguinal hernia repair were included as healthy controls. Nasopharyngeal
aspirates from all uninfected individuals were RSV negative. Gender, gestational age, presence of
breastfeeding, and presence of parental smoking were comparable between all groups. The study
protocols were approved by the Regional Committee on Research Involving Human Subjects Arnhem-
Nijmegen (serving as the IRB) and were conducted in accordance with the principles of the Declaration
of Helsinki. Written informed consent was obtained from the parents of all infants. A potential limitation
of our study is the difficulty of separating the presence of matAbs from endogenous RSV-induced
antibodies of the infant. However, with a median onset of disease of 3 days and the short time between
symptoms and hospitalization, production of endogenous RSV-IgG is unlikely to have reached significant
levels at the time of sampling. About 80% of patients were below 3 months of age. As Dutch infants in
general suffer their first respiratory infection after 3 to 7 months of age, infants in our study most likely
experienced a primary RSV infection (49). Therefore, it is plausible that we detected mainly matAbs (50).
Cells. Monkey kidney epithelial Vero-CCL81 cells were propagated in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 5% fetal calf serum (FCS) and 1% penicillin–streptomycin–
GlutaMAX (PSG). The Vero cell-derived cell line expressing FCGR2a (Vero2a) was described earlier (12),
and FCGR2a expression was confirmed by flow cytometry (data not shown). Monocytic THP-1 cells were
cultured in RPMI supplemented with 10% FCS and PSG (51). Peripheral blood mononuclear cells (PBMC)
were obtained from healthy volunteers. Blood was collected in heparin tubes, and the PBMC fraction was
isolated by density gradient centrifugation using Lymphoprep (Nycomed).
Virus and vaccine preparation. Live-attenuated recombinant RSV-X (rRSV) (52), recombinant RSV-X
containing a green fluorescent protein (GFP) gene (designated RSV [52]), and RSV-A2 were propagated
in Vero cells as described before (52) (Dutch GMO license IG-99-210). Virus stocks were purified between
layers of 10% and 50% sucrose by ultracentrifugation. FI-RSV and formalin-inactivated cell culture
supernatant were prepared from RSV-A2 as described previously (53).
Cotton rats. Cotton rats (Sigmodon hispidus) were held at the animal facilities of Intravacc (Nether-
lands), and experiments were approved by the Animal Ethical Committee of RIVM. Animals were
immunized intranasally with 105 infectious units of rRSV or with uninfected Vero cell supernatant (mock)
or intramuscularly with a high- or low-dose FI-RSV (1:5 and 1:125 diluted in phosphate-buffered saline
[PBS], respectively) on days 0 and 21. Animals were challenged intranasally with 105 infectious units of
RSV-A2 on day 49. Animals were sacrificed, blood plasma was collected, and lungs were fixed on day 53.
Histopathologic analysis of lung sections using hematoxylin and eosin staining was done by Paul Roholl
(Microscope Consultancy, Netherlands) as described previously (54). To prepare single-cell suspensions,
lung tissue of untreated animals was separated after DNase/collagenase digestion. Isolated lung cells
were phenotyped by staining with antibodies to an epithelial marker, pancytokeratin (18), and T cell
marker CD3 (19).
RSV infection and serology. THP-1 cells, human PBMC, or cotton rat lung cells were used to
measure ADE. Immune complexes were formed by preincubation of RSV with antibodies for 1 h at 37°C.
Cells were inoculated by spinoculation for 1 h at 700  g at 20°C in duplicate. Cells next were washed
with PBS and replenished with culture medium. Overnight incubation at 37°C was followed by flow-
cytometric analysis of GFP fluorescence using a FACSCanto II (BD Biosciences). RSV neutralization assays
were carried out on Vero and Vero2a cells. Assays were performed in triplicate as described earlier (52).
Fifty percent plaque reduction neutralization titers (PRNT50) were calculated from nonlinear regression
using PRISM (GraphPad) after normalization to antibody-untreated, RSV-infected samples. Spinoculation
had no effect on ADE or change of PRNT50s in any of the infection assays (data not shown). Antibody-
binding sites of FCGRs were blocked by adding 3 g/ml staphylococcal FLIPr-like protein (kind gift from
Kok van Kessel, University Medical Center Utrecht) (55) to THP-1 cells during RSV neutralization assays.
Cells were pretreated for 1 h and supplemented during infection and initial incubation steps. FLIPr-like
protein was removed with the inoculum.
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RSV-specific IgG concentrations in plasma samples were determined by enzyme-linked immunosor-
bent assay (ELISA) against RSV particles as described previously (6). IVIg at 1 mg/ml (KIOVIG; Baxter) was
referred to as 1 arbitrary unit.
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